Altimmune
ALT
37 hedge funds and large institutions have $39.9M invested in Altimmune in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 8 closing their positions.
49,183% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $12K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
35% more capital invested
Capital invested by funds: $29.6M → $39.9M (+$10.4M)
9% more funds holding
Funds holding: 34 → 37 (+3)
Top Buyers
| 1 |
JCI
Jet Capital Investors
New York
|
+$1.94M |
| 2 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
+$1.06M |
| 3 |
Renaissance Technologies
New York
|
+$280K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$255K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$140K |
Top Sellers
| 1 |
SC
Sophrosyne Capital
New York
|
-$1.28M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$604K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$360K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$186K |
| 5 |
Jane Street
New York
|
-$168K |
ALT Hedge Fund Activity: Q3 2013 in Review
37 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2013, worth a combined $39.9M — up 35% from $29.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALT positions and 8 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Jet Capital Investors, opening a new position worth an estimated $1.94M. The largest seller was Sophrosyne Capital, exiting entirely with an estimated $1.28M sold.
- 37 institutional investors held Altimmune (ALT) as of Q3 2013, up from 34 in Q2 2013.
- Funds reported $39.9M of Altimmune stock for Q3 2013, up 35% quarter-over-quarter.
- 12 funds opened new Altimmune positions in Q3 2013 and 8 closed out, a net change of +4 holders.
- The largest Altimmune buyer in Q3 2013 was Jet Capital Investors, an estimated $1.94M added.
- The largest Altimmune seller in Q3 2013 was Sophrosyne Capital, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2013.